The use of interferon in patients with “small triplet” hepatitis is not primarily concerned with short-term efficacy, but rather with assessing the possibility of a high recurrence rate, because the recurrence rate of “small triplet” hepatitis patients treated with interferon, even if it is effective in the short term, is very high, up to The rate of relapse is very high, up to 70% or more. The majority of hepatitis relapses within 1 year, but a few can be delayed to 3 years, and some can be more than 3 years. Interferon treatment has a lot of adverse effects, if you spend money and suffer, and finally more than 70% of them relapse, is not it wrong? So for most of the “small triple” hepatitis patients using interferon treatment is not the best choice, most are more suitable for longer-term treatment with entecavir or tenofovir. Who can try interferon therapy in patients with “minor triple-positive” hepatitis? For patients without contraindications to interferon, the following two groups of patients with “small triplet” hepatitis are more suitable to try interferon therapy. First, patients who have been treated with interferon for about a year to a year and a half and have a relatively low estimated relapse rate. Younger patients, patients on initial antiviral therapy, women, patients with low hepatitis B surface antigen quantification, HBVDNA quantification less than six copies, and patients with high ghrelin (more than three times the reference high) have a higher probability of achieving sustained immune control with a limited course of interferon therapy and may try interferon therapy. Patients with a more significant decrease in quantitative hepatitis B surface antigen within three months of interferon therapy have a lower likelihood of future relapse. Secondly, patients with hepatitis with a high risk of hepatocellular carcinoma, such as those with early cirrhosis and those with a family history of hepatocellular carcinoma, may consider preferring interferon therapy. The use of long-term treatment with entecavir or tenofovir can significantly reduce the incidence of hepatocellular carcinoma in patients with a high risk of hepatocellular carcinoma, but it cannot be completely avoided. Interferon has both antiviral and antitumor effects, and if a sustained virological response can be achieved with interferon therapy, the incidence of hepatocellular carcinoma can be minimized. For some patients with hepatitis “minor triplet” who are at high risk of liver cancer, if they relapse after a course of interferon therapy, a second or even a third interferon therapy can be considered. If economic conditions allow, try to choose long-acting interferon therapy, which can reduce the recurrence rate.